Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen ...

The produces oxygen concentrators for patients suffering from chronic respiratory conditions posted revenue of $80.1 million in the period. GOLETA, Calif., February 25, 2025--Inogen, Inc. (Nasdaq ...

Inogen shows solid B2B growth, but guidance and margin issues hurt sentiment. Learn why INGN stock is a speculative play with long-term growth potential.

For the year, the company reported a loss of $35.9 million, or $1.52 per share. Revenue was reported as $335.7 million. For the current quarter ending in March, Inogen said it expects revenue in ...

Inogen stock opened at $9.91 on Monday. The company has a market cap of $236.04 million, a price-to-earnings ratio of -4.40 and a beta of 1.02. The firm’s fifty day moving average is $10.17 and ...

16:31 EST Inogen (INGN) sees Q1 revenue $79M-$81M, one estimate $78.1M See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for ...

GAAP loss per share for the quarter was 41 cents, narrower than the year-earlier loss of $1.14per share. Inogen registered revenues of $80.1 million for the fourth quarter, up 5.5% year over year.

Welcome to Inogen’s Fourth Quarter 2024 Earnings Conference ... Total revenue for the third quarter of 2024 was $88.1 million, an increase of 5.5% compared to the prior year.

Reports Q4 revenue $80.1M, consensus $73.9M. “2024 was a stellar year for Inogen (INGN). With our new leadership team in place, we returned the Company to growth, achieved significant milestones ...

In the quarter under review, Inogen’s adjusted gross profit rose 25.4% from the year-ago level to $39.3 million. The adjusted gross margin expanded 777 basis points to 49.1%. Per management ...